Bell Global Emerging Companies Fund

Bell ASSET MANAGEMENT

Class A Fund Summary - Period ending 29 February 2024

Net Performance^

Returns in AUD	Fund	Index*
1 Month	5.2%	5.2%
3 Months	12.3%	12.0%
6 Months	6.6%	7.7%
1 Year	14.0%	14.5%
3 Years (pa)	9.4%	8.0%
5 Years (pa)	10.7%	9.4%
Inception (pa)^	11.1%	10.4%

* Index is the MSCI World SMID Cap Index. ^ The Bell Global Emerging Companies Fund was established in November 2012 under a different name and with a different investment strategy. The fund has operated under its current name and strategy since 27 June 2016 (Inception).

Top 10 Holdings

Company	Sector	Geography	Weight
Tractor Supply	Consumer Discretionary	US	2.8%
Charles River…	Health Care	US	2.7%
Paylocity Holding…	Industrials	US	2.7%
BJ's Wholesale Club…	Consumer Staples	US	2.6%
ICON plc	Health Care	US	2.6%
Genpact Ltd	Industrials	US	2.5%
Keysight Technologies,…	Information Technology	US	2.5%
Hong Kong Exchanges…	Financials	HK	2.5%
Techtronic Industries…	Industrials	HK	2.5%
Moncler S.p.A.	Consumer Discretionary	IT	2.5%

Best & Worst Performers - 1 Month

Top 5 - Relative Contribution	
ICON Plc	0.45%
Advanced Drainage…	0.44%
Charles River…	0.33%
Moncler SpA	0.27%
Coloplast A/S Class B	0.25%

Bottom 5 - Relative Contribution	
Amadeus IT Group SA…	-0.57%
Neste Corporation	-0.53%
Genpact Ltd	-0.25%
MSCI Inc. Class A	-0.20%
Bunzl plc	-0.16%

Sector Exposure



Communication Services	4.0%
Consumer Discretionary	14.4%
Consumer Staples	7.8%
Energy	1.8%
Financials	14.7%
Health Care	19.5%
Industrials	23.2%
Information Technology	9.5%
Materials	2.2%
[Cash]	2.8%

Geographic Exposure

Africa/Mideast	1.5%
Asia/Pacific Ex Japan	5.0%
Europe	30.7%
Japan	3.4%
North America	56.6%
[Cash]	2.8%

Investment Metrics#

	Portfolio	Index	Relative
Risk			
Total Risk	10.31	10.84	
Number of Stocks	49	5,012	
Active Share	98.1		
Value			
P/E (Fwd 12M)	20.8	16.1	129%
EV / EBITDA	15.4	12.1	127%
Growth (%)			
Sales Growth	11.4	13.3	86%
EPS Growth	14.2	15.2	93%
Quality			
Return on Equity	24.3	9.5	257%
Net Debt / EBITDA	0.5	2.0	25%
ESG			
MSCI ESG Overall Score	7.8	6.4	122%
Carbon Emissions*	19.1	146.7	13%

Investment Metrics calculated using FactSet database
* Scope 1+2 CO2 and equivalents per US$ mil. of revenue

Bell Global Emerging Companies Fund

Class A Fund Summary - Period ending 29 February 2024

Ned Bell CIO / Portfolio Manager

Adrian Martuccio Portfolio Manager

Contact Details

Bell Asset Management: Investment Manager
www.bellasset.com.au
Level 30, 101 Collins Street, Melbourne Victoria 3000.
Unitholder Enquiries Telephone: 03 9616 8619
Email: bellasset@unitregistry.com.au

Xanthe Virtue: Head of Wholesale & Platforms
T: +61 2 8000 8872. M: +61 413 450 163.
Email: xvirtue@bellasset.com.au

Channel Capital: Distribution Partner
www.channelcapital.com.au

Byron Slessar: Head of Key Accounts and Platforms
M: +61 400 592 592
Email: byron.slessar@channelcapital.com.au

Luke Mandekic: Head of Research and Consulting
M: +61 466 772 444
Email: luke.mandekic@channelcapital.com.au

Phelim O'Neill: Distribution Director
ACT | NSW
M: +61 436 029 775
Email: phelim.oneill@channelcapital.com.au

James Biggins: Distribution Director
VIC | SA | WA | TAS
M: +61 419 093 082
Email: james.biggins@channelcapital.com.au

Sam Mirls: Distribution Director
QLD
M: +61 422 777 909
Email: sam.mirls@channelcapital.com.au

Performance

Global equity markets continued to march higher during February, with the MSCI World SMID Cap Index rising 5.2%. The Bell Global Emerging Companies Fund (Class A) rose 5.2%, performing in-line with the MSCI World SMID Cap Index during the month.

Performance Attribution

The +5.2% portfolio return was driven mainly by holdings across the Consumer Staples, Health Care, Information Technology, Consumer Discretionary and Industrials sectors. Portfolio holdings in these five sectors combined make up nearly 75% of the total portfolio, with each sector returning over 4% during the month. From a regional perspective, gains in the US stocks led the way. Currency was a slight tailwind to returns in AUD terms as the Aussie dollar softened during the month. From a relative attribution perspective, the slight outperformance in February was driven mainly by good stock picking within the Health Care and Consumer Staples sectors.

In terms of stock specifics, the best stock performer during the month was Icon which rallied over 20%. Icon is one of the world's leading contract research organisations (CRO) which partners with pharma and biotech companies to help run their clinical trials. The company reported solid 4Q23 results, reiterated 2024 guidance for mid-high teens EPS growth and provided supportive commentary around solid RFP activity. The biopharma funding environment has also improved, providing further support from a near term sentiment perspective and, if sustained, should be a tailwind over the medium to long term for earnings prospects. Having increased our position in Icon meaningfully on the back of share price weakness in late 2022 and early 2023, we have taken advantage of the recent share price strength to trim some profits. However, with solid double-digit earnings growth set to continue and the valuation at attractive levels (forward P/E ratio ~20x), we continue to like the investment case looking forward.

Other positive contributors to performance during February included Advanced Drainage (Industrials), Charles River Labs (Health Care), Moncler (Consumer Discretionary) and Tractor Supply (Consumer Discretionary).

One of the largest negative contributors to performance in February was Amadeus, a Spanish technology company that specialises in software solutions for the travel and tourism industry. The company reported 4Q23 results and 2024 revenue guidance which were broadly in-line with expectations but disappointed slightly in terms of margin and FCF guidance. The stock also sold off late in the month due to speculation that Amadeus was considering the acquisition of US payment processor Shift4. Following month end, Amadeus management issued a statement saying that they were not interested in acquiring Shift4 and shares have subsequently started to rebound. Our positive outlook for the company remains unchanged and we took advantage of the recent share price weakness to add to the position.

Other performance detractors included Neste (Energy), Genpact (Industrials), MSCI (Financials) and Bunzl (Industrials).

Market Commentary

The global equity market rally continued in February with the MSCI World SMID Cap Index rising over 5% (in AUD terms) during the month. The strong returns were broad based by region, with the US market once again leading the way. At a sector level, Information Technology, Industrial and Consumer Discretionary stocks were the best performers, while stocks in the Real Estate, Communication Services and

Utilities sectors failed to keep up in the strong market.

From a style perspective, 'Growth' stocks again did the heavy lifting, outperforming the 'Value' cohort by approx. 3.5%. This extends the outperformance of 'Growth' stocks to approx. 25% over the past 12 months (MSCI World Growth Index +38% vs MSCI World Value Index +13%, in USD terms). Both SMID Caps and Large Caps posted solid gains during February, with Large Caps marginally outperforming. This means that the relative valuation differential between SMID Caps and Large Caps remains close to historical trough levels. As a result, there continues to be many great investment opportunities in the SMID Cap part of the market given the more attractive valuations, combined with the superior growth prospects for many companies at this end of the market cap spectrum.

The 'Magnificent 7' saw some diverging fortunes during the month, as NVIDIA and Meta Platforms (both 25%+) continued their rapid ascent after posting strong quarterly results, while Apple and Alphabet both lagged the market.

Economic conditions have been holding up well, especially with respect to the all-important labour market where unemployment rates remain at or near historical lows in many key regions, including 3.7% in the US, 3.8% in the UK, 6.0% in the EU and 2.4% in Japan. Inflation is generally cooling but came in a little hotter than expected in the US during January (CPI 3.1% vs. 2.9% forecast). The market has subsequently pushed back expectations for the timing of interest rate cuts in the US, with the consensus view that we will only see 3 cuts in 2024 compared to the 6 anticipated at the start of the year. This contributed to a rise in bond yields, including the US 5 year and 10 year treasury yields expanding 30-40bps to 4.25% (still well below October 2023 levels).

Elsewhere, the surge in Japanese stocks continued with the Nikkei 225 Index finally eclipsing the peak achieved in December 1989. It has been a lengthy wait for long suffering Japanese investors. The favourable equity market conditions in Japan continued despite the Japanese economy dipping into a technical recession in the second half of 2023. This caused Japan to lose its position as the world's third largest economy to Germany. In China, equity markets bounced (MSCI China Index +8%) as the Chinese Lunar New Year holiday showed solid activity levels and the government announced new measures to support markets, including further curbs on short selling and stock purchases by state owned investment firms.

Portfolio Activity

There were two new stocks introduced to the portfolio during the month: MonotaRO (Industrials) and Humana (Health Care).

MonotaRO is a Japanese B2B ecommerce company which sells a wide variety of industrial supplies that businesses need to function but are not their primary product, such as personal protective equipment, hand tools, lab supplies, cleaning supplies, building materials etc. End market exposure is diversified, with key industries serviced including Manufacturing, Construction and Auto. The market remains very fragmented and MonotaRO is well placed to take share given their scale and breadth of products sold (over 22m items in their catalogue), with customers attracted to the convenience and price competitiveness of their offering. We have been following the company for a long period of time and admired the company's strong track record of consistent growth (10-year revenue CAGR +20% and EPS CAGR +24%). We expect solid double-digit earnings growth to continue and with the valuation pulling back significantly in recent years, believe that now is an opportune time to establish a position in this quality compounder.

Humana is a leading managed care company in the US, with a strong market position in Medicare Advantage (privately run health plans for over 65's), which is a growing segment of the market aided by ageing demographics and increasing penetration compared to traditional Medicare (offered by the government). The company's share price has pulled back materially over the past year due to a number of factors weighing on earnings including higher medical costs associated with a greater uptick in health care utilisation and softer Medicare Advantage enrolment trends. We view some of the headwinds as being more temporary in nature and believe that guidance now includes relatively conservative assumptions, providing potential for earnings to surprise to the upside looking forward. While the negative sentiment may not turn immediately, we see an attractive risk/reward profile for long term investors at current levels.

We also added to a number of existing holdings which we believe have strong upside potential including Agilent (Health Care), Paylocity (Industrials) and Techtronic (Industrials).

To fund these purchases we trimmed some profits in a number of holdings which have continued to charge higher including Cencora (Health Care), Advanced Drainage (Industrials), Houlihan Lokey (Financials) and Check Point Software (Information Technology).

Research

Our research agenda has been very active as usual, with the first part of the month mainly focused on the tail-end of quarterly reporting season. More recently we have had several team members embark on overseas research trips to get up close and personal with the management teams of companies held in the portfolio, watchlist names and others where we think we can garner important insights. So far this has included attendance at various industry conferences across the Industrials, Consumer and Financials sectors, along with many meetings at corporate headquarters. Some of the initial high-level takeaways include:

- Consumer – the US consumer continues to spend at healthy levels, with the strong employment conditions and wage inflation remaining supportive. While consumer savings balances are coming down, in many situations they are still at levels higher than pre-COVID and other factors such as strong equity markets also help with confidence and financial security. There are pockets of weakness, especially amongst the lower income demographic and a number of companies have noted signs of down trading behaviour, so we are watching closely for any broad-based deterioration. For now, the consumer is generally in good shape.
- M&A activity showing signs of picking up – we heard from a wide range of industry participants, including a number of M&A advisory groups, that there are more M&A deals in the pipeline than there has been for some time. With market participants gradually adjusting to a higher rate environment and bid/ask spreads getting narrower in some situations, there is an expectation that deals previously on the back burner have a higher likelihood of getting completed. If deal activity does pick up, this should bode well for the small and mid-cap end of the market which are often acquisition targets.
- Investments in AI, digitalisation and automation – unsurprisingly, one of the most recurring themes in our discussions has been the topic of AI, along with digitalisation and automation. Most managements have flagged investments in these areas as a high priority.
- Supply chains and inventory levels – supply chain bottlenecks and inventory levels are largely getting back to more normalised levels. Issues in the Red Sea and Suez Canal have led to a spike in certain container shipping rates but we have not heard too much concern from corporates about the risk at this stage.
- US election – in the lead up to the November 2024 election, the US political landscape continues to garner a lot of media attention, however most of the companies we have spoken with played down any potential impacts to their business. There is a lot to still play out in this respect, but the fact that the two current leading Presidential candidates are known quantities provides some comfort on what is to come (even if some of their actions can be very unpredictable).
- Pricing tailwinds abating – for many consumer companies the contribution to organic growth from pricing in 2024 will be significantly lower than we have seen over the past couple of years. As a result, we are hearing companies talk about the more relevant role that volumes will need to play moving forward. Increased innovation and product launches should help in this respect but there is risk that some companies, especially those with weaker brand propositions, may resort to increased promotional or discounting activity.
- Commercial real estate – the office market continues to face a lot of pressures but most other segments of the commercial real estate market including multi-family, industrial and retail are generally holding up fine.
- Employment – while employment conditions remain tight, most management teams we have spoken to have indicated that wage inflation trends have decelerated and the ability to attract and retain employees is much easier than it was over the past year or two.

With more travel and many more meetings taking place in the next couple of weeks we will share more detailed insights in the near future.

Outlook

The outlook for global equities remains broadly positive. There are hints of the more speculative behaviour that we saw in 2020/21 creeping back in and valuations in certain pockets of the market are starting to look a little frothy but overall we are still finding many attractive investment opportunities in the current market, especially in the small and mid-cap segment.

At this stage we don't see any major risks on the horizon that may derail positive momentum but conscious of not becoming too complacent and are always looking at our investments through a risk-adjusted lens.

We continue to make gradual tweaks to the portfolio and some of our positioning has arguably taken a bit longer than usual to pay off, but we remain confident with the overall quality of the stocks held and believe the portfolio is well positioned with an excellent combination of upside potential and downside protection characteristics.

Key Features

Investment Objectives	Outperform the index over rolling three year periods
Asset Allocation	Long only global small and mid cap equities, No gearing, No derivatives
Investment Style	Fundamental bottom up approach "Quality at a reasonable price"
Investment Highlights	• A diversified portfolio of small and mid cap (SMID) global stocks • 'Quality' focus - consistently high returning companies • Long-term horizon - typically 3-5 year holding periods • Benchmark agnostic • Diversified portfolio structure • Maximum cash position 10% • Highly experienced investment team
Benchmark	MSCI World SMID Cap Index
Currency Exposure	Unhedged
Investment Timeframe	At least 5 years
Number of Holdings	30 - 60

Fund Terms

Fund Inception Date	November 2012
Strategy Inception Date	27 June 2016
Product Structure	Registered Managed Investment Scheme
Investment Manager	Bell Asset Management
Responsible Entity	Bell Asset Management
Custodian	National Australia Bank
mFund Code	Code: BLM01
Unit Pricing & Liquidity	Daily Published on www.bellasset.com.au & market data services Applications using application form attached to the PDS Redemptions typically paid out within 10 days
Minimum Investment	Minimum investment – $10k Minimum transaction – $5k
Indirect Cost Ratio	1.34% p.a No performance fees, No entry or exit fees
Buy / Sell Spread	+/-0.10%
Reporting	Transaction confirmations upon transacting, annual periodic statement, tax statement, distribution statement and Annual Financial Report
Income	Annual distribution of taxable income
Target Market	The Fund is likely to be consistent with the financial situation and needs of a consumer who is seeking capital growth with at least a 5 year investment timeframe and who is unlikely to need to withdraw their money on less than one week's notice. The Fund is intended for use by consumers with a Medium or higher risk and return profile, depending on the proportion of their Investable Assets which is allocated to the Fund.